ABSTRACT
Methods: Tissue samples were identified from our prospective observational protocol. The radiosensitivity index (RSI) 10-gene assay was run on samples and calculated alongside the GARD by using the previously published algorithms. A cohort of 105 patients with 137 lung metastases treated with stereotactic body radiation therapy (SBRT) at our institution was used for clinical correlation.
Results: A total of 138 unique metastatic lung lesions from our institution's tissue biorepository were identified for inclusion. There were significant differences in the RSI of lung metastases on the basis of histology. In order of decreasing radioresistance, the median RSIs for the various histologic types of cancer were endometrial adenocarcinoma (0.49), soft-tissue sarcoma (0.47), melanoma (0.44), rectal adenocarcinoma (0.43), renal cell carcinoma (0.33), head and neck squamous cell cancer (0.33), colon adenocarcinoma (0.32), and breast adenocarcinoma (0.29) (p ¼ 0.002). We modeled the GARD for these samples and identified the biologically effective dose necessary to optimize local control. The 12-and 24-month Kaplan-Meier rates of local control for radioresistant versus radiosensitive histologic types from our clinical correlation cohort after lung SBRT were 92%/87% and 100%, respectively (p ¼ 0.02).
Conclusions:
In this analysis, we have noted significant differences in radiosensitivity on the basis of primary histologic type of lung metastases and have modeled the biologically effective dose necessary to optimize local control. This study suggests that primary histologic type may be an additional factor to consider in selection of SBRT dose to the lung and that dose personalization may be feasible.
Introduction
The management of oligometastatic disease has become increasingly common among radiation oncologists. 1 One of the primary sites in which radiation therapy is utilized in this setting is for the management of lung metastases. Stereotactic body radiation therapy *Corresponding author.
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(SBRT) is an excellent treatment approach, with control rates higher than 90% reported in both prospective and retrospective series. [2] [3] [4] Several studies have discussed the role that primary histologic type may have in local control outcomes after SBRT for lung metastases. [4] [5] [6] [7] Some reports have suggested that colorectal metastases may be more prone to local recurrence, 4 whereas others have suggested that rectal cancer may be more likely to locally recur than colon primaries. 5 The radiosensitivity index (RSI) is a previously developed and extensively validated gene signature for assessment of the inherent radiosensitivity of tumors. [8] [9] [10] [11] [12] Our group previously reported on use of the RSI with metastatic disease in the setting of colon primaries and metastases 13 according to anatomical location and brain 14 and liver metastases 15 according to primary histologic type. When assessing liver metastases, we noted that differences in the RSI of surgically resected samples correlated with local control rates after fivefraction SBRT at our institution. 15 We noted that histologic types determined to be radioresistant on the basis of their RSI (such as colorectal) fared worse in terms of local control than did more radiosensitive histologic types such as breast, lung, and anal cancers.
We have previously developed the genomically adjusted radiation dose (GARD) as a method of personalizing radiation dose. 16 Significant differences were noted in the modeled GARD between clinically radiosensitive tumors (including cervical and oropharyngeal cancers) and clinically radioresistant tumors (such as glioblastoma and sarcoma). The GARD predicted clinical outcomes in five independent data sets and has been noted to be the first personalized approach to radiation delivery and a priority for clinical trial application. 17, 18 In this manuscript, we undertook an analysis of the RSI of lung metastases in our center's tissue biorepository and have proposed a model for dose personalization by using the GARD to identify tissue samples that would be likely to benefit from dose escalation beyond a 100 Gy biologically effective dose (BED). These results were correlated with an independent data set for patients treated with lung SBRT at our institution.
Patients and Methods
Patients were identified from the institutional review board-approved Total Cancer Care (TCC) prospective observational protocol at Moffitt Cancer Center. 19 Data on a total of 138 unique metastatic lung lesions were obtained from the TCC data pool for patients treated at Moffitt Cancer Center.
RNA Preparation and Gene Expression Profiling
These methods have been described previously. 16 Briefly, gene expression values for the samples in this study were extracted from the TCC database. These expression values were normalized against a median sample by using the previously reported iterative rank order normalization method. 20 An RNA quality-related batch effect was identified in the resulting normalized data and was removed by training a partial least squares model 21 to the RNA integrity number and then subtracting the first partial least squares component.
Radiosensitivity Signature
The previously tested 10-gene assay was run on tissue samples ranked according to gene expression. The RSI was calculated by using the previously published rank-based algorithm. 8, 9 Each of the 10 genes in the assay was ranked according to gene expression (from the highest expressed [10] to the lowest expressed [1] ). The RSI was determined by using the previously published rank-based linear algorithm:
GARD
The formulation of the GARD has been previously described. 16 GARD scores were derived by using the linear quadratic model and the individual gene expression-based RSI. We calculated the GARD by using a script written into Excel (Microsoft, Redmond, WA). The final GARD formula is GARD ¼ nd (a þ bd). The GARD was modeled for a dose of 84 Gy in 2 Gy fractions, the equivalent dose at 2 Gy (EQD2) of 50 Gy in five fractions using a value of a/b of 10. An 8.4% failure rate was assumed with a 100 Gy BED. 22 The calculation for the GARD is similar to that for the BED, except that the patient-specific a is derived by substituting the RSI for survival in S ¼ e
, where S is survival, d is dose (d ¼ 2 Gy), n is equal to 1, and b is a constant (0.05/ Gy). 23 A higher GARD value predicts a higher therapeutic effect of radiation.
Lung SBRT Cohort
Our institutional database of patients treated with SBRT to the lung was used to conduct a retrospective analysis on all consecutive patients treated for lung metastases with a dose of 50 Gy in five fractions or 60 Gy in five or eight daily fractions. Each patient was immobilized by using the BodyFIX dual vacuum immobilization system (Medical Intelligence, Schwabmünchen, Germany). Axial computed tomography (CT) images were obtained on a 16-slice CT simulator (GE HealthCare, Milwaukee, WI) with 3-mm-thickness image acquisition. Four-dimensional CT imaging was performed by using the Varian Real-Time Position Management System (Varian, Palo Alto, CA). In some cases, respiratory gating was used by placing an infrared reflector on the patient's chest. Before each treatment, an initial cone beam CT scan was acquired, a match was performed, and the shift was applied. Any shift greater than 0.3 cm required a second cone beam CT acquisition to verify position. The planning target volume equaled the gross tumor volume plus 7 mm superiorly and inferiorly and 5 mm radially. The planning target volume was covered by 95% of the prescribed dose. Dose constraints included the spinal cord 0.03 cc less than 17 Gy, lung V20 less than 10%, mean lung dose less than 600 cGy, esophagus V27.5 less than 5 cc, chest wall V30 less than 30 cc, heart mean less than 10 Gy, heart V32 less than 15 cc, and brachial plexus V30 less than 3 cc.
After treatment, lesions were followed by the treating radiation oncologist or medical oncologist with imaging at 2-to 3-month intervals. Radiologic imaging was reviewed to determine local control. An independent review of imaging to assess local control was undertaken by a radiation oncologist (K.A.A.) and a radiologist (J.A.A.). Local failure was defined by an increase in the size of the previously irradiated area according to the Response Evaluation Criteria in Solid Tumors version 1.1 24 and distinguished from postradiation change on the basis of continued growth of tumor on subsequent imaging. Direct RSI measurements for this cohort were not performed because of tissue unavailability. To classify each histologic type as either radiosensitive or radioresistant, we utilized the median RSI observed in the genomically profiled tissue institutional biorepository. When a previously reported median RSI cutpoint (RSI ! 0.375) for radioresistance 13 was used, the histologic types determined to be radioresistant by the RSI included soft-tissue sarcoma (n ¼ 29 
Statistical Analysis
Descriptive statistics, including median and range for continuous variables or counts and percentages for categorical variables, were used to summarize the cohort. When comparing RSI values between groups, the Kruskal-Wallis test was used. To test differences between cohorts, the Wilcoxon, Pearson chi-square, and Fisher exact tests were used when appropriate. Overall survival and local control rates were calculated from the last day of treatment to the date of death or progression by using the Kaplan-Meier (KM) method. Cox proportional hazard model analyses were performed. A two-tailed p value less than 0.05 was considered statistically significant. Statistical analyses were performed with JMP 13 software (SAS Institute Inc, Cary, NC). Box plots were generated by using MATLAB software (version R2013a, Natick, MA). 
Results

The RSI of Lung Metastases
GARD Modeling
When the GARD was modeled for a total delivered dose of 84 Gy in two fractions (which is the EQD2 equivalent of the 100 Gy BED, 10 Gy Â 5 SBRT fractionation), we noted a large heterogeneity in the GARD values across histologic types. The median delivered GARD values in the various histologic types in increasing order were endometrial adenocarcinoma, 29.8; soft-tissue sarcoma, 31.7; melanoma, 34.7; rectal adenocarcinoma, 35.2; HNSCC, 46.7; renal cell carcinoma, 47.2; colon adenocarcinoma, 47.7; and breast adenocarcinoma, 51.5 [p ¼ 0.002]. When modeling an 8.4% failure rate, we identified 11 lesions in our data set that were at risk for local failure. These lesions received a median GARD of 17.5 (range 8.5-24.8) and were identified inferior to the red line in Figure 2 . These lesions all had an RSI of at least 0.55 and were of sarcoma and melanoma primary histologic type. Figure 3 details the BED for 2 Gy fractions required for lesions to achieve a GARD of at least 25.1, which is the minimum GARD required for local control as predicted by our model. Interestingly, a sigmoidal relationship is observed where the largest influence of dose occurs in the range of a 50 Gy to 100 Gy BED. In this BED range, 22% to 90% of patients achieved an optimized GARD. Between a 100 Gy and 200 Gy BED, however, only an additional 7% of patients achieved an optimized GARD.
Clinical Outcomes after Lung SBRT
A total of 105 patients treated to 137 metastatic lung lesions with SBRT were identified at our institution for clinical correlation. Patients were treated between August 2007 and March 2017. A total of 66 lesions (48%) were from histologic types identified as radiosensitive (on the basis of their RSI) in our biorepository and 71 (52%) were from histologic types identified as radioresistant (as determined by their RSI). The median follow-up for lesions was 16 months (range 1.2-88.9 months). Clinical characteristics for the two cohorts are detailed in Table 1 . There was no difference between the two groups in terms of age (p ¼ 0.14), sex (p ¼ 0.13), maximum diameter of the metastases (p ¼ 0.2), number of lines of previous systemic therapy before SBRT (p ¼ 0.97), or SBRT dose (p ¼ 0.18).
Five local failure events were noted, for overall 12-month and 24-month KM local control rates of 96% and 93%. All local failures occurred in histologic types determined to be radioresistant on the basis of RSI. These included two sarcoma lesions, two rectal lesions, and one melanoma. One rectal lesion was treated to 60 Gy in eight fractions and one sarcoma lesion was treated to 50 Gy in five fractions; the three others were treated to 60 Gy in five fractions. The characteristics of these five cases of local failure are detailed in Table 2 . Significant differences in local control were noted between radioresistant and radiosensitive histologic types. The 12-and 24-month local control rates determined by the KM method were 92%/87% and 100%, respectively (p ¼ 0.02) (Fig. 4) . Other factors such as dose of 60 Gy in five fractions versus others (p ¼ 0.39) and size of at least 1.5 cm versus less than 1.5 cm (p ¼ 0.66) were not found to be predictive for local control on univariate analysis.
The overall survival rates in the cohort at 12 and 24 months were 90% and 72%, respectively. No differences were noted in overall survival between the radioresistant and radiosensitive cohorts (90% and 71% 
Discussion
In this article, we have detailed the results of genomic profiling of lung metastases on the basis of RSI. We have noted significant differences between lung metastases according to primary histologic type. Radioresistant histologic types identified by RSI were noted to include endometrial adenocarcinoma, soft-tissue sarcoma, melanoma, and rectal adenocarcinoma, whereas renal cell carcinoma, HNSCC, colon adenocarcinoma, and breast adenocarcinoma were noted to be (comparatively) radiosensitive. By modeling the GARD for an EQD2 of 50 Gy in five fractions, we identified lesions at risk of local failure and candidates for potential dose optimization in future personalized SBRT dosing trials. These results were similar to the results in our independent institutional cohort of metastatic lung lesions treated with lung SBRT.
Several studies have reported on the impact that histology can have in the outcome of SBRT-treated lung metastases. These include studies revealing that colorectal metastases may fare worse after lung SBRT treatment than other histologic types. A study from Binkley et al. reported that colorectal metastases had a significantly higher cumulative incidence of local failure than did other histologic types, with 24-month local failure rates of 42% versus 9% (p < 0.0004). 4 However, this lower local control for colorectal metastases may be due to rectal lesions faring worse than those of the colon. A study from Kinj et al. revealed that there was a significant difference between local control of colon metastases and local control of rectal metastases after lung SBRT. 5 The study suggested that one of the reasons for this difference may be an inherent radioresistance in rectal tumors owing to the routine use of neoadjuvant radiation in primary management of the disease and recurrent cells arising from radioresistant clones, as well as to a higher rate of KRAS mutations in rectal lesions. Similar results have been noted by de Baere et al., with rectal metastases faring worse in local control compared with colon metastases after radiofrequency ablation of lung metastases. 25 Our local control outcomes also support the findings of these two studies. We noted two local failures in rectal lesions but none in colon lesions. Although differences in local control were noted in our series by primary histologic type, the overall local control rate is high as reported by other institutions. 1 Furthermore, we noted a separation of colon and renal lung samples into both radioresistant and radiosensitive populations on the basis of RSI, a finding that could be explored in future analyses.
Various dose and fractionation schedules for lung SBRT have been studied in the retrospective and prospective settings. The only study to assess the effect of two SBRT schedules in the prospective setting for primary NSCLC has been RTOG 0915. 26 No differences in tumor control were noted between 34 Gy in one fraction and 48 Gy in four fractions. 27 The ongoing TROG 13.01 SAFFRON II study is assessing 28 Gy in one fraction versus 48 Gy in four fractions in pulmonary oligometastases. 28 However, the BEDs of these two fractionation schemes are very similar: 106.4 and 105.6, respectively. With high rates of local control, decreasing toxicity and treatment burden is the primary goal of the TROG 13.01 study. The optimal SBRT dose and fractionation for lung metastases remains an open question.
Onishi et al. noted an 8.4% failure rate after a delivered BED of 100 Gy. 22 We modeled the expected distribution of GARD values achieved with a uniform 100 Gy BED and identified significant heterogeneity achieved in GARD values in spite of a uniform physical dose. Our model proposes that patients with a GARD value less than 25.1 are at higher risk for recurrence. A total of 11 lesions in our cohort would have met this criterion. These lesions have an RSI of at least 0.55 and represent a cohort of patients that may benefit from genomically guided dose optimization beyond a 100 Gy BED. These 11 lesions were of melanoma and sarcoma primary histologic type. Similarly, we noted that three of the five failures in our clinical cohort were of melanoma and sarcoma primary histologic type. Finally, we modeled the BED in 2 Gy equivalent fractions required to achieve a GARD of at least 25.1, which is the minimum GARD required to achieve local control as predicted by our model. The sigmoidal shape of the curve indicates that the greatest influence of dose occurs in the range of a 50 Gy to 100 Gy BED, whereas 3% of lesions (n ¼ 4) continue to be at risk of local failure past a 200 Gy BED. We hypothesize that the GARD can be applied as a method of dose personalization in the setting of SBRT to lung metastases. Although, the current analysis offers a novel approach to personalization of lung SBRT dose, our study is not without limitations. The primary limitation of this analysis is that the RSI values are not available for our clinical correlation cohort of lesions treated with SBRT. The RSI was run on resected surgical tissue from our institution's biorepository, and this tissue was used as a model to determine the impact of primary histologic type on the basis of RSI. In addition, there are a few disease sites (breast, head and neck, and endometrium) for which there are limited (<5) RSI samples, which limits the ability to draw conclusions for these tumors. However, our results utilize the previously validated GARD metric for radiation dose personalization and support the impact that primary histologic type has on local control after lung SBRT.
In this study, we have noted significant differences in lung metastases on the basis of primary histologic type. We have also proposed a method of personalization to tailor radiation dose to the genomic profile of lung metastases. As we move closer to an era in which personalization of radiation dose to an individual tumor may become a reality, practitioners may pay closer attention to primary histologic type in the management of oligometastatic disease.
